Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A promising new option for tough-to-treat stomach cancer. The Phase 3 G-HOPE-001 trial found that arcotatug tavatecan — a claudin 18.2-targeting antibody-drug conjugate — significantly improved both progression-free and overall survival compared to physician's choice chemotherapy in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. The drug also demonstrated a manageable safety profile with durable responses.
A new contender in late-line gastric cancer treatment. The first interim analysis of the randomized, open-label Phase 3 G-HOPE-001 trial has delivered encouraging results for patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA) — a population with historically limited options. Arcotatug tavatecan (IBI343/TAK-921), an antibody-drug conjugate targeting claudin 18.2, significantly outperformed treatment of physician's choice (TPC) on key survival endpoints.
Patients receiving arcotatug tavatecan showed meaningful improvements in both progression-free survival (PFS) and overall survival (OS) compared to those on standard chemotherapy. Responses were durable, and the safety profile was described as manageable — an important consideration for a heavily pre-treated patient population.
Key Takeaways:
Why it matters: Advanced gastric and GEJ cancers carry a poor prognosis, especially in later lines of therapy. If confirmed, these results could position arcotatug tavatecan as a meaningful new standard of care for claudin 18.2-positive patients who have exhausted earlier treatment options.
